Belite Bio (BLTE) Q4 2025 earnings summary

Executive summary

• Achieved positive topline results in the pivotal Phase III DRAGON trial for tinlarebant in Stargardt disease (STGD1), meeting primary efficacy endpoints with a 35.7%–36% reduction in atrophy lesion growth rate versus placebo, supporting a planned NDA submission in Q2 2026.

• Completed enrollment in the DRAGON II and PHOENIX phase III trials, advancing the pipeline for STGD1 and geographic atrophy (GA), with 72–75 subjects in DRAGON II and 430–530 in PHOENIX.

• Raised $402 million through an underwritten public offering, closing the year with $772.6 million in cash, equivalents, and U.S. Treasury holdings to support commercialization and pipeline expansion.

Financial highlights

• Q4 2025 GAAP net loss was $25.3 million, compared to $10.1 million in Q4 2024; non-GAAP net loss was $13.6 million versus $5.9 million.

• Full-year 2025 GAAP net loss was $77.6 million, up from $36.1 million in 2024; non-GAAP net loss was $38.7 million versus $27.2 million.

• R&D expenses for 2025 were $45.4 million (up from $29.9 million); SG&A expenses were $38.8–$38.9 million (up from $10.1 million).

• Q4 2025 GAAP total operating expenses were $28.1 million, up from $11.5 million in Q4 2024.

• Cash, cash equivalents, and U.S. Treasury holdings totaled $772.6 million at year-end 2025, up from $145.2 million at end of 2024.

Outlook and guidance

• NDA submission for tinlarebant in STGD1 is planned for Q2 2026, with commercialization preparations underway and key leadership hired.

• U.S. launch targeted for Q1 2027, with an initial sales team of 25–30 focused on genetic testing and brand awareness.

• U.S. regulatory approval is the top priority, with ex-U.S. submissions to follow, prioritizing EMA and Japan.

• Commercialization and R&D activities expected to require $300–$350 million over the next three years.

• Interim analysis planned for the PHOENIX trial in GA.